Drug news
Bronchitol gets "negative trend" vote at CHMP for Cystic Fibrosis
Pharmaxis is unlikely to receive a positive EU opinion for its cystic fibrosis therapy Bronchitol (inhaled mannitol) following a "negative trend" vote from the CHMP. The drug is intended for the treatment of cystic fibrosis and has been approved in Australia and is not yet filed in the USA.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.